Moderna publishes presentation on phase I intismeran study in resected pancreatic cancer
Bitget2026/10/25 13:32- Moderna published phase I study results for adjuvant intismeran autogene with FOLFIRINOX in 20 patients with resected pancreatic ductal adenocarcinoma.
- Neoantigen-specific T-cell responses were detected in all 19 evaluable patients, including during concurrent chemotherapy.
- At median follow-up of approximately 17 months, 11 patients remained recurrence-free.
- One patient experienced grade 3 intismeran-related fatigue; no adverse events led to intismeran discontinuation.
- No deaths were reported; analyses were descriptive, with no formal hypothesis testing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver
Driven by booming semiconductor exports, South Korea's current account surplus in September surged to a record high.
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.
AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).
Crypto prices
More
